Additionally, a monoclonal antibody targeting glycosylated PD-L1 not only blocks the PD-L1/PD-1 interaction but also promotes PD-L1 degradation and induces direct cancer cell killing, suggesting that glycosylation targeting may enhance immune checkpoint therapy in breast cancer [57]. This evidence concerns the gene CD274 and breast carcinoma.